On this page you can find clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the drop-down lists below to find clinical trials by condition, status, phase and country.
Only interventional studies that have started within the last 20 years and completed within the 2 last years will be displayed.
The study results will be available on ClinicalTrials.gov from 12 months after the end of the study.
Last Data Refreshed @ 07-May-2025 01:10:11 UTC
Filters
Condition
Status
Phase
Country
Showing : 1 – 5 of 140 clinical trials
Upper Limb Spasticity
Dysport
United States of America (the)
Canada
France
Active, Not Recruiting
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.
Primary Sclerosing Cholangitis
Iqirvo
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Canada
Germany
Italy
Spain
Portugal
Active, Not Recruiting
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis.
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the study drug. The trial will also study the study drug’s effects on blood tests and other tests related to PSC disease activity.
Fibrodysplasia Ossificans Progressiva
fidrisertib
Mexico
Portugal
Belgium
Netherlands (Kingdom of the)
Spain
Sweden
Canada
China
France
Australia
Italy
Korea (the Republic of)
Japan
Argentina
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Active, Not Recruiting
A study to assess the effectiveness and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility (ankyloses) of major joints with cumulative and irreversible loss of movement and disability. This study will evaluate the efficacy of 2 dosing regimens of IPN60130 in inhibiting new HO volume compared with placebo (a dummy treatment) in adult and paediatric participants with FOP. It will be assessed by a scan (provides internal images of the body) called low dose Whole Body Computed Tomography (WBCT), excluding head. Adults and participants 5 years of age or older are also eligible for a sub study to evaluate HO lesions assessed by another type of scan, Fluorine-18-labelled natrium fluoride Positron Emission Tomography-Computed Tomography ([18F]NaF PETCT ). This will be a 3-part study: Part A will be a 12-month, 3-arm, parallel-group, randomised, double-blind, placebo-controlled period during which participants will be randomised to low or high weight-based IPN60130 dosage arms or placebo, Part B will be a 12-month, 2-arm, randomised, double-blind period during which participants will receive high or low weight-based daily dosages of IPN60130. Participants completing Part A will enter Part B: placebo recipients from Part A will be randomised to one of the IPN60130 dosage arms with a 1:1 ratio, whereas participants receiving IPN60130 will remain in their respective dosage arms. Part C will be a 36-month, extension period. All participants completing Part B will continue in the same IPN60130 treatment arm for additional 36-month treatment in Part C.
Spasticity
IPN10200
Czechia
Bulgaria
Hungary
Germany
Austria
Poland
Spain
United States of America (the)
Active, Not Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
The purpose of the study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
Advanced Solid Tumors
Diffuse Large B-cell Lymphoma
Epitheliod Sarcoma
Follicular Lymphoma
Mesothelioma
Non-Hodgkin Lymphoma
Renal Medullary Carcinoma
Synovial Sarcoma
Tazverik
United Kingdom of Great Britain and Northern Ireland (the)
United States of America (the)
Ukraine
Poland
Belgium
Australia
France
Active, Not Recruiting
A study to assess the long-term safety of tazemetostat
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy. The aim of the study will be to assess the long-term safety of tezemetostat.